ORMP Earnings & Financial Statements
Oramed Pharmaceuticals Inc.
$4.18
-$0.19(-4.35%)
49
Overall
80
Value
20
Tech
47
Quality
Market Cap
$182.20M
Volume
93.47K
52W Range
$2.09 - $5.47
Target Price
$7.00
ORMP earnings and financial statements: Oramed Pharmaceuticals Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ORMP Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $2.00M | - | $1.34M | $2.70M | $2.70M |
| Cost of revenue | $1.99M | - | - | - | - |
| Operating income | -$15.09M | -$12.78M | -$15.77M | -$40.60M | -$124.0K |
| EBITDA | $75.44M | -$14.87M | $2.23M | -$37.61M | -$24.15M |
| Net income | $64.05M | -$19.06M | $5.09M | -$36.56M | -$22.24M |
| EPS (diluted) | $1.50 | $-0.48 | $0.14 | $0.94 | $0.78 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $230.86M | $155.28M | $220.55M | $161.64M | $128.00M |
| Total liabilities | $31.08M | $9.90M | $57.66M | $10.49M | $11.48M |
| Shareholders’ equity | $199.74M | $146.26M | $163.82M | $151.81M | $115.77M |
| Cash and equivalents | $45.95M | $54.42M | $9.05M | $40.46M | $77.25M |
| Long-term debt | $540.0K | $156.0K | $342.0K | $647.0K | $403.0K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$9.14M | -$8.41M | -$10.29M | -$27.92M | -$21.18M |
| Capital expenditure | -$9.0K | -$18.0K | -$254.0K | -$496.0K | -$375.0K |
| Free cash flow | -$9.15M | -$8.43M | -$10.55M | -$28.41M | -$21.56M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ORMP | $4.18 | -4.3% | 93.47K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Oramed Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW